» Articles » PMID: 39866746

From Isolation to Detection, Advancing Insights into Endothelial Matrix-bound Vesicles

Overview
Date 2025 Jan 27
PMID 39866746
Authors
Affiliations
Soon will be listed here.
Abstract

Matrix-bound vesicles (MBVs), an integral part of the extracellular matrix (ECM), are emerging as pivotal factors in ECM-driven molecular signaling. This study is the first to report the isolation of MBVs from porcine arterial endothelial cell basement membranes (A-MBVs) and thyroid cartilage (C-MBVs), the latter serving as a negative control due to its minimal vascular characteristics. Using Transmission Electron Microscopy (TEM), Nano-Tracking Analysis (NTA), Electrochemical Impedance Spectroscopy (EIS), and Atomic Force Microscopy (AFM), we orthogonally characterized the isolated MBVs. We detected the presence and preservation of vascular endothelial cadherin (CD144) in A-MBVs, its low to non-detetcted in C-MBVs, in which SOX9, a chondrocyte marker, was detected. Moreover, we developed a prototype of an immuno-functionalized screen-printed electrode designed for the immunoadsorption of CD144+ MBVs. This device facilitated the electrochemical detection of the targeted vesicles and allowed for their subsequent topological characterization using AFM, which verified the integrity and morphology of CD144+ MBVs post-immunoadsorption. These advancements enhance our comprehension of MBVs as conveyors of tissue-specific signals and pioneer new avenues for harnessing their cargo in biomedical applications. This research sets a significant precedent for future studies on the application of MBVs in regenerative medicine and ECM signaling.

References
1.
Guimaraes A, Correia A, Alves B, da Silva R, Martins J, Pego-Fernandes P . Evaluation of a Physical-Chemical Protocol for Porcine Tracheal Decellularization. Transplant Proc. 2019; 51(5):1611-1613. DOI: 10.1016/j.transproceed.2019.01.042. View

2.
Huleihel L, Hussey G, Naranjo J, Zhang L, Dziki J, Turner N . Matrix-bound nanovesicles within ECM bioscaffolds. Sci Adv. 2016; 2(6):e1600502. PMC: 4928894. DOI: 10.1126/sciadv.1600502. View

3.
Takahashi Y, Takakura Y . Extracellular vesicle-based therapeutics: Extracellular vesicles as therapeutic targets and agents. Pharmacol Ther. 2023; 242:108352. DOI: 10.1016/j.pharmthera.2023.108352. View

4.
Hussey G, Dziki J, Lee Y, Bartolacci J, Behun M, Turnquist H . Matrix bound nanovesicle-associated IL-33 activates a pro-remodeling macrophage phenotype via a non-canonical, ST2-independent pathway. J Immunol Regen Med. 2019; 3:26-35. PMC: 6814021. DOI: 10.1016/j.regen.2019.01.001. View

5.
Biehl A, Gracioso Martins A, Davis Z, Sze D, Collins L, Mora-Navarro C . Towards a standardized multi-tissue decellularization protocol for the derivation of extracellular matrix materials. Biomater Sci. 2022; 11(2):641-654. PMC: 9844390. DOI: 10.1039/d2bm01012g. View